An examination of the seven stages of the immune cycle in groups with elevated versus reduced ARPC1A expression revealed that increased ARPC1A levels correlated with lower TIP scores across most cancer types, suggesting possible immunosuppressive effects within the TME (Figure 5C). Here, ARPC1A is linked to cancer.